Followers | 1077 |
Posts | 80255 |
Boards Moderated | 6 |
Alias Born | 03/10/2009 |
Friday, June 14, 2019 10:15:08 PM
In conjunction with the proposed offering described below, on June 14, 2019, Ampio Pharmaceuticals, Inc. (the “Company”) and Canaccord Genuity LLC (“Canaccord”) terminated that certain Equity Distribution Agreement (the “Agreement”), dated April 12, 2019, by and between Canaccord and the Company.
The Agreement implemented an “at-the-market” equity offering program under which the Company, from time to time, could offer and sell shares of its common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $24,650,000, through Canaccord. The Company sold 254,984 shares of its Common Stock for net proceeds of $142,321.16 pursuant to the Agreement. The Company provided Canaccord with customary indemnification rights, and Canaccord was entitled to a fixed commission of 3.0% of the gross proceeds from Common Stock sold under the Agreement.
Item 8.01 Other Events
On June 14, 2019, the Company issued a press release announcing the commencement of a proposed offering of shares of its common stock in an underwritten public offering. The Company intends to grant the underwriters a 45-day option to purchase additional shares of its common stock. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
The press release announcing the commencement of the proposed offering is attached hereto as Exhibit 99.1, and is incorporated by reference herein.
STOP & VISIT MY BOARD AT: HOTTEST PENNY STOCK PICKS
http://investorshub.advfn.com/boards/board.aspx?board_id=19627
My posts are NOT a buy/sell recommendation, Do your Own DD, before you buy any stock - I reserve the right to buy/sell any stock
Recent AMPE News
- Ampio Announces Voluntary Delisting and SEC Deregistration • PR Newswire (US) • 03/25/2024 09:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 03/05/2024 05:15:29 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 08:49:00 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 02/28/2024 08:48:05 PM
- Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments • Edgar (US Regulatory) • 02/28/2024 08:47:17 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 02/28/2024 08:46:20 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 02/28/2024 08:45:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/15/2024 02:31:23 PM
- Ampio Provides Update on Results from Pre-IND Enabling Studies • PR Newswire (US) • 02/14/2024 10:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/25/2024 09:31:28 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/25/2024 09:18:53 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/24/2024 10:16:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 09:20:20 PM
- Ampio Provides Litigation Update - Reports Settlement in Principle of Certain Pending Legal Actions • PR Newswire (US) • 01/11/2024 09:15:00 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 12/21/2023 09:25:42 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 09:10:40 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/02/2023 01:30:24 PM
- Ampio Pharmaceuticals to Present at the Emerging Growth Conference • PR Newswire (US) • 10/31/2023 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/27/2023 06:10:26 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2023 06:56:04 PM
- Ampio Selects Ascendia Pharmaceuticals, Inc. to Provide CDMO Services to Support Clinical Development of OA-201 • PR Newswire (US) • 10/05/2023 08:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/04/2023 08:15:24 PM
- Ampio Pharmaceuticals to Present at the Emerging Growth Conference • PR Newswire (US) • 09/26/2023 01:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/22/2023 08:30:43 PM
FEATURED POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • Mar 27, 2024 10:52 AM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM